When was Charnwood Molecular founded?

Charnwood Molecular was founded in 1998 and raised its 1st funding round 22 years after it was founded.

Where is Charnwood Molecular located?

Charnwood Molecular is headquartered in Loughborough, United Kingdom.

How many employees does Charnwood Molecular have?

As of May 31, 2026, the latest employee count at Charnwood Molecular is 17.

Is Charnwood Molecular a funded company?

Charnwood Molecular is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Jan 12, 2020.

When was the latest funding round of Charnwood Molecular?

Charnwood Molecular's latest funding was a $***** PE round on Apr 29, 2021, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In United Kingdom, the Biopharma Outsourcing sector has seen $20.7M in funding in 2026 to date.

Where does Charnwood Molecular rank among its competitors?

Charnwood Molecular ranks 118th amongst 234 active competitors, of which 21 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ChemLex, which secured $45M in Dec, 2025.

Who are the top competitors of Charnwood Molecular?

Charnwood Molecular's top competitors include Sai Life Sciences, NFIL and IRBM. Among them, ChemLex secured the most recent funding round in December, 2025.

Charnwood Molecular - 2026 Company Profile, Team, Funding & Competitors

Company Details

Charnwood-Molecular is a CRO offering drug discovery services, especially medicinal and synthetic chemistry services for pharmaceutical, biotechnology and chemical industries. Their service portfolio includes medicinal chemistry (which includes Lead Discovery, Lead Optimisation and Development), Process Research Development (Pre-clinical non-GMP supply, Process Chemistry R&D etc.), Custom Synthesis (Advanced and complex intermediates, Monomers for library generation, Metabolites and reference standards) and their proprietary ULTImate YChemH (developed with the support of European funding under the Eurostars programme) - a compound profiling technology to study interactions between small molecules and protein targets. The company has collaborations with other companies such as Xenogesis, Hybrigenics, Reach Separations and few others.

Website: charnwood-molecular.com
Social
Email ID: *****@charnwood-molecular.com
Phone Number: +44 **********

Key Metrics

Founded Year

1998

Location

Loughborough, United Kingdom

Stage

Late Stage

Latest Funding Round

PE, Apr 29, 2021, $*****

Investors

Synova

Ranked

118^th among 234 active competitors

Employee Count

17 as on May 31, 2026

Investment & Acquisitions

Aurelia Bioscience

Similar Companies

Sai Life Sciences & 271 more

View Charnwood Molecular's full profile

Charnwood Molecular has raised funding over 2 rounds. Its first funding round was on Jan 12, 2020. Its latest funding round was a PE round on Apr 29, 2021 for $*****. 1 investor participated in its latest round. Charnwood Molecular has 1 institutional investor.

Here is the list of recent funding rounds of Charnwood Molecular:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 29, 2021	4973789	PE	1252144	6031794	5568193	2658608
Jan 12, 2020	9419447	PE	6938645	5328455	Synova	5411779

Access funding benchmarks and valuations. Sign up today!

View details of Charnwood Molecular's funding rounds and investors

The founders of Charnwood Molecular is Phil Page.

Here are the details of Charnwood Molecular's key team members:

Phil Page: Founder of Charnwood Molecular.

View details of Charnwood Molecular's Founder profiles and Board Members

Charnwood Molecular's employee count trend

Charnwood Molecular has 17 employees as of May 26. Here is Charnwood Molecular's employee count trend over the years:

Employee count trend for Charnwood Molecular

Uncover Charnwood Molecular's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Charnwood Molecular include Sai Life Sciences, NFIL and IRBM. Here is the list of Top 10 competitors of Charnwood Molecular, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sai Life Sciences 1999, Hyderabad (India), Public	Provider of drug discovery, development, and manufacturing of complex small molecules	$108M	Sequoia Capital, HBM Healthcare Investments ... & 123 others	66/100
2nd	NFIL 1967, Mumbai (India), Public	CRAMS company specialising in the custom chemical synthesis and manufacturing of fluorinated compounds	-	-	50/100
3rd	IRBM 2010, Pomezia (Italy), Funding Raised	Integrated drug discovery and preclinical development service provider	-	Europa, BioVaria	48/100
4th	Medicilon 2004, Pudong (China), Funding Raised	Integrated drug discovery and preclinical development services	-	Spinnotec, Fortune Capital & 1 others	47/100
5th	ChemLex Shanghai (China), Series B	Provider of consulting services in the field of chemical research and development through artificial intelligence chemical synthesis	$71M	LYFE Capital, Granite Asia & 3 others	46/100
6th	Bioduro 2005, San Diego (United States), Acquired	Global CRDMO providing integrated drug discovery, development, and manufacturing services	-	BridgeWest Group	45/100
7th	Alzheimer's Drug Discovery 1998, New York City (United States), Funding Raised	Foundation aims to discover drugs to prevent, treat, and cure alzheimer's disease	-	HHS	45/100
8th	48Hour Discovery 2017, Edmonton (Canada), Funding Raised	Developer of molecular discovery platform	-	K-Startup Grand Challenge, Edmonton	44/100
9th	Alfa Chemistry 2015, Ronkonkoma (United States), Unfunded	Supplier of research chemicals, reagents, custom synthesis, and analytical services	-	-	43/100
10th	Vernalis 1999, Wokingham (United Kingdom), Acquired	Drugs for the treatment of cough, asthma, migraine and cancer.	-	Invesco Mutual Fund, Thuja Capital & 4 others	43/100
118th	Charnwood Molecular 1998, Loughborough (United Kingdom), Late Stage	CRO offering medicinal and synthetic chemistry services	-	Synova	24/100